SPGL008单药或联合卡介苗在非肌层浸润性膀胱癌中的安全性、耐受性和初步抗肿瘤活性的I /II 期临床研究
一般药物都追求长效化，但是三生在SPGL008研发时进行工程优化追求短效化。
SPGL008 has engineered modifications in the Fc region to shorten its half-life and reduce drug exposure in peripheral circulation. These optimizations significantly mitigated toxic side effects while maintaining anti-tumor efficacy.